L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
Clinical approaches to vaccination in oncology.
TL;DR: Standardised techniques for the accurate assessment of the individual immune phenotype before and during the trial are needed to allow for the identification of the sub-group of patients who will respond favourably to treatment, and the precise definition of immune parameters in these patients will lead the way for optimised treatment procedures.
Journal ArticleDOI
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Karin Hohloch,Carsten Oliver Sahlmann,Vijai J. Lakhani,Gerald Wulf,Bertram Glass,Justin Hasenkamp,Johannes Meller,Joachim Riggert,Lorenz Trümper,Frank Griesinger +9 more
TL;DR: Tandem transplants consisting of HD chemotherapy followed by HD-RIT with 131I-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL.
Journal ArticleDOI
Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network
Karin Hohloch,H. K. Lankeit,Pier Luigi Zinzani,Christian Scholz,Michael Lorsbach,Christine Windemuth-Kieselbach,Lorenz Trümper +6 more
TL;DR: Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data.
Journal ArticleDOI
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma.
TL;DR: Responses to repeated immunotherapy with rituximab were observed in approximately one third and two thirds of initially responding patients with aggressive B cell lymphoma and mantle cell lymphomas, respectively, but not in primarily refractory disease.
Journal ArticleDOI
The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Kevin Mellert,Melanie Martin,Jochen K. Lennerz,Manuel Lüdeke,Annette M. Staiger,Annette M. Staiger,Markus Kreuz,Markus Löffler,Norbert Schmitz,Lorenz Trümper,Alfred C. Feller,Sylvia Hartmann,Martin-Leo Hansmann,Wolfram Klapper,Harald Stein,Andreas Rosenwald,German Ott,Marita Ziepert,Peter Møller +18 more
TL;DR: Comparing published data of whole exome and transcriptome sequencing of a large DLBCL cohort confirmed that predicted deleterious SOCS1 mutations forecast pre‐eminent survival in early onsetDLBCL.